Document is current
Any future updates will be listed below
-
Authors
Marijam, Alen https://orcid.org/0000-0003-1046-9702
Vroom, Nikki
Bhavsar, Amit
Posiuniene, Inga
Lecrenier, Nicolas
Vroling, Hilde
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
- License Information
-
More Information
Article History
Received: 4 January 2024
Accepted: 15 March 2024
First Online: 24 April 2024
Declarations
:
: Amit Bhavsar, Alen Marijam, Inga Posiuniene and Nicolas Lecrenier are employed by and hold shares in GSK. Hilde Vroling and Nikki Vroom are employees of P95/Pallas. P95/Pallas received funding from GSK for the submitted work. P95/Pallas holds/held contracts with AstraZeneca, GSK, Pfizer, Sanofi and Seqirus, Orchard, BioMarin, Daiichi, Bavarian Nordic and Bayer. The authors declare no other financial and non-financial relationships and activities and no conflicts of interest.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
: Shingrix is a trademark owned by or licensed to GSK. Zostavax is a trademark of MSD.
